BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21047491)

  • 1. Bevacizumab in combination with fluoropyrimidine-based chemotherapy for the first-line treatment of metastatic colorectal cancer.
    Whyte S; Pandor A; Stevenson M; Rees A
    Health Technol Assess; 2010 Oct; 14(Suppl. 2):47-53. PubMed ID: 21047491
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis.
    Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; El-Rayes BF; Flowers CR
    J Clin Oncol; 2015 Apr; 33(10):1112-8. PubMed ID: 25691669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.
    Pan QZ; Zhao JJ; Liu L; Zhang DS; Wang LP; Hu WW; Weng DS; Xu X; Li YZ; Tang Y; Zhang WH; Li JY; Zheng X; Wang QJ; Li YQ; Xiang T; Zhou L; Yang SN; Wu C; Huang RX; He J; Du WJ; Chen LJ; Wu YN; Xu B; Shen Q; Zhang Y; Jiang JT; Ren XB; Xia JC
    Signal Transduct Target Ther; 2024 Apr; 9(1):79. PubMed ID: 38565886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.
    Adams RA; Meade AM; Seymour MT; Wilson RH; Madi A; Fisher D; Kenny SL; Kay E; Hodgkinson E; Pope M; Rogers P; Wasan H; Falk S; Gollins S; Hickish T; Bessell EM; Propper D; Kennedy MJ; Kaplan R; Maughan TS;
    Lancet Oncol; 2011 Jul; 12(7):642-53. PubMed ID: 21641867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003.
    Kim TW; Taieb J; Gurary EB; Lerman N; Cui K; Yoshino T
    Future Oncol; 2021 Dec; 17(36):5013-5022. PubMed ID: 34779646
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study.
    Takashima A; García-Alfonso P; Manneh R; Beşen AA; Hong YS; Cuyle PJ; Yanez P; Burge M; Yoshino T; Kim TW; Cui K; Li C; Jain R; Adelberg D; Taieb J
    Eur J Cancer; 2024 Mar; 205():114036. PubMed ID: 38749110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal Antibodies for First-Line Treatment of Metastatic Colorectal Cancer.
    Liao PF; Wu TW; Peng TR
    Am J Ther; 2024 May-Jun 01; 31(3):e286-e297. PubMed ID: 35972911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapies in the management of colorectal carcinoma: role of bevacizumab.
    Puthillath A; Patel A; Fakih MG
    Onco Targets Ther; 2009 Feb; 2():1-15. PubMed ID: 20616890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visceral fat and clinical outcome in patients receiving first-line chemotherapy with bevacizumab for metastatic colorectal cancer.
    Cazeneuve N; Bouché O; Leger J; Borg C; Labbe-Devilliers C; Lucidarme O; Tasu JP; Manfredi S; Aubé C; Trillaud H; Manzoni P; Marcus C; Terrebonne E; Douillard JY; Chautard R; Lobet S; Scotto B; Bleuzen A; Lecomte T
    Clin Res Hepatol Gastroenterol; 2024 May; 48(7):102380. PubMed ID: 38788975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expert consensus on maintenance treatment for metastatic colorectal cancer in China.
    Xu RH; Shen L; Li J; Xu JM; Bi F; Ba Y; Bai L; Shu YQ; Liu TS; Li YH; Bai CM; Yuan XL; Zhang J; Chen G; Zhou AP; Yuan Y; Wang XJ; Qian XP; Deng YH
    Chin J Cancer; 2016 Jan; 35():13. PubMed ID: 26769299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XELOX vs FOLFOX-4 as first-line therapy for metastatic colorectal cancer: NO16966 updated results.
    Cassidy J; Clarke S; Díaz-Rubio E; Scheithauer W; Figer A; Wong R; Koski S; Rittweger K; Gilberg F; Saltz L
    Br J Cancer; 2011 Jun; 105(1):58-64. PubMed ID: 21673685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal.
    Whyte S; Pandor A; Stevenson M
    Pharmacoeconomics; 2012 Dec; 30(12):1119-32. PubMed ID: 23058097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
    Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
    Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical effectiveness and cost-effectiveness of cetuximab (mono- or combination chemotherapy), bevacizumab (combination with non-oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of metastatic colorectal cancer after first-line chemotherapy (review of technology appraisal No.150 and part review of technology appraisal No. 118): a systematic review and economic model.
    Hoyle M; Crathorne L; Peters J; Jones-Hughes T; Cooper C; Napier M; Tappenden P; Hyde C
    Health Technol Assess; 2013 Apr; 17(14):1-237. PubMed ID: 23547747
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC).
    Lawrence D; Maschio M; Leahy KJ; Yunger S; Easaw JC; Weinstein MC
    J Med Econ; 2013 Dec; 16(12):1387-98. PubMed ID: 24102083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using pharmacoeconomic modelling to determine value-based pricing for new pharmaceuticals in malaysia.
    Dranitsaris G; Truter I; Lubbe MS; Sriramanakoppa NN; Mendonca VM; Mahagaonkar SB
    Malays J Med Sci; 2011 Oct; 18(4):32-43. PubMed ID: 22589671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada.
    Hedden L; Kennecke H; Villa D; Johnston K; Speers C; Kovacic L; Renouf DJ; Peacock S
    Eur J Cancer; 2012 Sep; 48(13):1969-76. PubMed ID: 22325838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of XELOX versus XELOX plus bevacizumab for metastatic colorectal cancer in a public hospital school.
    Ungari AQ; Pereira LRL; Nunes AA; Peria FM
    BMC Cancer; 2017 Oct; 17(1):691. PubMed ID: 29041915
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
    Rivera F; Valladares M; Gea S; López-Martínez N
    J Med Econ; 2017 Jun; 20(6):574-584. PubMed ID: 28107090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-Effectiveness of Cetuximab as First-line Treatment for Metastatic Colorectal Cancer in the United States.
    Shankaran V; Ortendahl JD; Purdum AG; Bolinder B; Anene AM; Sun GH; Bentley TGK
    Am J Clin Oncol; 2018 Jan; 41(1):65-72. PubMed ID: 26398184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.